CEFDINIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefdinir, and what generic alternatives are available?
Cefdinir is a drug marketed by Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, Lupin, Sandoz, and Teva Pharms. and is included in twelve NDAs.
The generic ingredient in CEFDINIR is cefdinir. There are twelve drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cefdinir profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefdinir
A generic version of CEFDINIR was approved as cefdinir by LUPIN on May 19th, 2006.
Summary for CEFDINIR
Recent Clinical Trials for CEFDINIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assistance Publique - Hôpitaux de Paris | Phase 4 |
Mercy Health Ohio | Phase 2 |
Northeast Ohio Medical University | Phase 2 |
Pharmacology for CEFDINIR
Drug Class | Cephalosporin Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CEFDINIR
US Patents and Regulatory Information for CEFDINIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkem Labs Ltd | CEFDINIR | cefdinir | CAPSULE;ORAL | 210220-001 | Feb 19, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Teva Pharms | CEFDINIR | cefdinir | FOR SUSPENSION;ORAL | 065332-002 | May 4, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Alkem Labs Ltd | CEFDINIR | cefdinir | FOR SUSPENSION;ORAL | 210534-001 | Feb 19, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |